GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its target price upped by Morgan Stanley to $238.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
GWPH has been the subject of a number of other reports. BidaskClub cut shares of GW Pharmaceuticals PLC- from a sell rating to a strong sell rating in a research note on Wednesday, July 24th. ValuEngine cut shares of GW Pharmaceuticals PLC- from a buy rating to a hold rating in a research note on Thursday, August 1st. Oppenheimer boosted their price objective on shares of GW Pharmaceuticals PLC- from $234.00 to $239.00 in a research note on Wednesday. Guggenheim restated a buy rating and issued a $222.00 price objective (up from $186.00) on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, May 7th. Finally, Zacks Investment Research cut shares of GW Pharmaceuticals PLC- from a buy rating to a hold rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. GW Pharmaceuticals PLC- has a consensus rating of Buy and a consensus price target of $208.91.
NASDAQ GWPH opened at $166.37 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.81 and a quick ratio of 7.19. The firm has a market capitalization of $4.56 billion, a PE ratio of -15.75 and a beta of 2.25. The company has a 50 day simple moving average of $167.74. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.96. The firm had revenue of $72.04 million during the quarter, compared to analysts’ expectations of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The company’s revenue was up 2096.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.25) earnings per share. On average, analysts expect that GW Pharmaceuticals PLC- will post -6.72 EPS for the current fiscal year.
In related news, insider Julian S. Gangolli sold 671,928 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $14.84, for a total transaction of $9,971,411.52. Following the transaction, the insider now owns 510,352 shares of the company’s stock, valued at $7,573,623.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William A. Waldegrave sold 3,576 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $15.00, for a total transaction of $53,640.00. Following the transaction, the director now directly owns 3,576 shares in the company, valued at approximately $53,640. The disclosure for this sale can be found here. Insiders sold 1,047,660 shares of company stock valued at $15,647,815 over the last 90 days. 3.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in GWPH. Amundi Pioneer Asset Management Inc. increased its position in GW Pharmaceuticals PLC- by 53.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,300 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 800 shares during the period. Advisory Services Network LLC increased its position in GW Pharmaceuticals PLC- by 23.1% during the fourth quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 96 shares during the period. Chartwell Investment Partners LLC bought a new position in GW Pharmaceuticals PLC- during the first quarter worth $2,380,000. Lake Street Financial LLC bought a new position in GW Pharmaceuticals PLC- during the first quarter worth $1,167,000. Finally, Paragon Capital Management LLC bought a new position in GW Pharmaceuticals PLC- during the first quarter worth $34,000. 78.87% of the stock is currently owned by institutional investors and hedge funds.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Read More: Death Cross
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.